Leading pharmaceutical innovation

Leading Pharmaceutical Innovation

Volumn , Issue , 2008, Pages 1-186

  Gassmann, Oliver ^a   Reepmeyer, Gerrit ^a   Von Zedtwitz, Maximilian ^b  

^a UNIVERSITY OF ST GALLEN   (Switzerland)

^b AsiaCompete Int'l Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889984816     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-77636-9     Document Type: Book

References (141)

1. Accenture (2001a): High Performance Drug Discovery - An Operating Model for a New Era. Executive Briefing. Accenture Report.
2. Accenture (2001b): R&D and the Internet. Accenture Report.
3. Accenture (2002): Commercial and R&D: Reinventing the relationship. Pharmaceuticals & medical products. Accenture White Paper.
4. Agarwal, S.; Desai, S.; Holcomb, M. M.; Oberoi, A. (2001): Unlocking the Value in Big Pharma. The McKinsey Quarterly, 2001, No. 2.
5. Albers, S.; Eggers, S. (1991): Organisatorische Gestaltungen von Produktinnovations-Prozessen. Führt der Wechsel des Organisationsgrades zu Innovationserfolg? Zeitschrift für Betriebswirtschaftliche Forschung, Vol. 43, Iss. 1, pp. 44-64.
6. Arthur D. Little (2003): Aktuelle Trends bei Buyouts in der Chemie- und Pharmaindustrie. Market Study, January 2003.
7. Arthur D. Little, Solvias (2002): External Synthesis Services for Research and Development in the Pharmaceutical Industry. Market Study, June 2002.
8. BAK (2001): Garant und Motor für Produktivität und Wohlstand in der Schweiz - Bedeutung der chemisch/pharmazeutischen Industrie für die Schweizer Volkswirtschaft. Baseler Konjunkturforschung: Basel.
9. Baumann (2003): The Challenge of Innovation in the Drug Discovery Process. Presentation at CTO-Roundtable 'Management of Pharmaceutical R&D in Turbulent Times - Perspectives and Trends'. Zurich, March 2003.
10. BCG (2001): A Revolution in R&D - How Genomics and Genetics are Transforming the Biopharmaceutical Industry. BCG Report: Boston, MA.
11. Becker, S.; Kellermann, C.; Menz, W.; Sablowski, T. (1999): Struktur und Vernetzung der Biotechnologie-Industrie. Arbeitsbericht des Projektes "Vernetzung als Wettbewerbsfaktor". Johann Wolfgang Goethe Universität, Frankfurt/Main.
12. Booz Allen & Hamilton (1997): In Vivo, Making Combinatory Chemistry Pay. Booz Allen & Hamilton Report: New York.
13. Borgulya, P. (2000): F. Hoffmann-La Roche: Global Differentiation between R and D. In: Boutellier, R.; Gassmann, O.; von Zedtwitz, M. (Editors): Managing Global Innovation. 2nd edition. Heidelberg: Springer, pp. 236-248.
14. Boutellier, R.; Gassmann, O.; Von Zedtwitz, M. (1999): Managing Global Innovation: Uncovering the Secrets of Future Competitiveness. 2nd ed., Springer: Berlin, Tokyo, New York.
15. BPI (1999): Die 'Innovationsschere'ader pharmazeutischen Industrie. Taken from Prof. Homburg & Partner (2001): Trends und Chancen in der Pharma-Branche. Mannheim, April 2001.
16. Brueckner, M.; Philipp, M. P.; and Luithle, J. E. (2005): China's Pharmaceutical Market: Business Environment and Market Dynamics. In: Festel, G.; Kreimeyer, A.; Oels, U.; von Zedtwitz, M. (2005, Editors): The Chemical and Pharmaceutical Industry in China - Challenges and Threats for Foreign Companies. Springer: Heidelberg, pp. 91-107.
17. Buchanan, I. P. M. (2002): R&D Collaborations - a Partners' Perspective. Vertex Pharmaceuticals. Presentation held in Zurich on 27 February 2002.
18. Buderi, R; Weber, J.; Hoots, C.; Neff, R. (1991): A Tighter Focus for R&D. Business Week, 2 December 1991, pp. 80-84.
19. Budworth, D. W. (1996): Finance and Innovation. New York.
20. Cantwell, J. (1995): The Globalisation of Technology: What Remains of the Product Cycle Model? In: Cambridge Journal of Economics, Vol. 19, pp. 155-174.
21. Cap Gemini Ernst & Young (2001): Perspectives on life science. Issue 3.
22. CDER (2002): Center for Drug Evaluation and Research at FDA: http://www.fda.gov/cder/, accessed September 2002.
23. Chen, W. (2004): Looking For an Industry Cure. China International Business, Issue 204, 34-37.
24. Chesbrough, H. (2003): Open Innovation: The New Imperative for Creating and Profiting from Technology. Harvard Business School Press: Boston, MA.
25. Chesbrough, H. (2006): Open Business Models: How to Thrive in the New Innovation Landscape. Harvard Business School Press: Boston, MA.
26. Dalton, D. H.; Serapio, M. G. (1995): Globalizing Industrial Research and Development. Washington, D. C.: U. S. Department of Commerce.
27. Datamonitor (2003): Licensing Strategies: Benchmarking Analysis of the Top 20 Pharmaceutical Companies. April 2003, p. 52.
28. Davis, S.; Botkin, J. (1994): The Coming of Knowledge-Based Business. Harvard Business Review, 5, pp. 165-170.
29. Deck, M.; Strom, M. (2002): Model of Co-development Emerges. In: Research Technology Management, May-June, pp. 47-53.
30. De Meyer, A. (1991): Tech Talk: How Managers Are Stimulating Global R&D Communication. In: Sloan Management Review, 32, 3, pp. 49-58.
31. Di Masi, J. (2001): Tufts Center for the Study of Drug Development Pegs Costs of a New Prescription Drug at $802 Million. Press release, Tufts University, 30 November 2001.
32. Economiesuisse (2006): F+E in der Schweizerischen Privatwirtschaft. Zürich.
33. Ernst & Young (2002): Beyond Borders - The Global Biotechnology Report 2002. Global Health Sciences. Ernst&Young Report.
34. Federal Social Insurance Office (2002): http://www.bsv. admin. ch/, accessed September 2002.
35. Federal Statistical Office (1998): Costs of Public Health Care. Bern. http://www.statistik.admin. ch/, accessed September 2002.
36. Federal Statistical Office (1999): Costs of Public Health Care. Bern. http://www.statistik.admin. ch/, accessed February 2003.
37. Festel, G.; Polastro, E. (2002): Dritte arbeiten häufig kostengünstiger. In: Chemische Rundschau, Vol. 55, No. 13, 28June 2002, p. 7.
38. Freudenheim, M.; Peterson, M. (2001): The Drug-Price Express Runs into a Wall. In: The New York Times, 23 December 2001, p. 3.
39. Gassmann, O. (1997): Internationales F&E-Management - Potentiale und Gestaltungskonzepte transnationaler F&E-Projekte. Oldenbourg: München, Wien.
40. Gassmann, O. (2001): E-Technologien in dezentralen Innovationsprozessen. Zeitschrift für Betriebswirtschaft, Supplementary Edition 3/2001, pp. 73-90.
41. Gassmann, O. (2006): Opening up the Innovation Process: Towards an Agenda. In: R&D Management, Vol. 36, No. 3, pp. 223-226.
42. Gassmann, O.; Han, Z. (2004): Motivations and Barriers of Foreign R&D Activities in China. In: R&D Management, Vol. 34, No. 4, pp. 423-437.
43. Gassmann, O.; Keupp M. M. (2007): The Competitive Advantage of Early and Rapidly Internationalising SMEs in the Biotechnology Industry: A Knowledge Based View. In: Journal of World Business, Special Issue: The Early and Rapid Internationalisation of the Firm, Vol. 42, pp. 350-366.
44. Gassmann, O.; Von Zedtwitz, M. (1998): Organization of Industrial R&D on a Global Scale. In: R&D Management, Vol. 28, No. 3, pp. 147-161.
45. Gassmann, O.; Von Zedtwitz, M. (1999): New Concepts and Trends in International R&D Organization. In: Research Policy, Vol. 28, pp. 231-250.
46. Gassmann, O.; Von Zedtwitz, M. (2003): Trends and Determinants of Managing Virtual R&D Teams. In: R&D Management, Vol. 33, No. 3, pp. 243-262.
47. Gassmann, O.; Reepmeyer, G. (2003): Innovationspotentiale im Successful Ageing in der Schweiz. Unpublished report conducted for the Swiss Federal Office for Professional Education and Technology. Bern.
48. Gassmann, O.; Reepmeyer, G. (2006): Wachstumsmarkt Alter, Innovationen für die Zielgruppe 50+, Hanser: München, Wien.
49. Gassmann, O.; Reepmeyer, G.; Von Zedtwitz, M.; (2003): Analyzing Structures of the Pharmaceutical Industry in Switzerland. In: Journal of Health Care and Society, Vol. 13, No. 2.
50. Grabowski, H.; Vernon, J.; Di Masi, J.; (2002): Returns on Research and Development for 1990s New Drug Introductions. In: Pharmacoeconomics 20, Suppl. 3(December 2002), pp. 11-29.
51. Greis, N. P.; Dibner, M. D.; Bean, A. S. (1995): External Partnering as a Response to Innovation Barriers and Global Competition in Biotechnology. In: Research Policy, Vol. 24, pp. 609-630.
52. Gueth, A. (2001): Entering into an Alliance with Big Pharma. Benchmarks for Drug Delivery Contract Service Providers. In: Pharmaceutical Technology, October 2001, pp. 132-135.
53. Handelszeitung (2002): Pharmamarkt wächst rasant. Handelszeitung, No. 16, 17 April 2002, p. 1.
54. Herrling, P. L. (1998): Maximizing Pharmaceutical Research by Collaboration. In: Nature, Vol. 392, Supp. 30April 1998, pp. 32-35.
55. Hofmann, D. (1997): Das virtuelle Unternehmen. Neue Zürcher Zeitung, 25 October 1997, p. 29.
56. Hofstede, G. (1980): Culture's Consequences: International Differences in Work Related Values. Beverly Hills.
57. Homburg & Partner (2001): Trends und Chancen in der Pharma-Branche. Mannheim, April 2001.
58. Houston, J. G.; Banks, M. (1997): The Chemical-Biological Interface: Developments in Automated and Miniaturised Screening Technology. In: Current Opinion in Biotechnology, 8, pp. 734-740.
59. IBM Business Consulting Services (2003): A Survey of Strategic Licensing Practices in the Pharmaceutical Industry. IBM Institute for Business Value Executive Brief, accessed at: http://www.ibm.com/bcs.
60. IHA-IMS (2002): http://www.ihaims.ch, accessed September 2002.
61. IHA-IMS Health (2002): Taken from Handelszeitung (2002): Pharmamarkt wächst rasant. Handelszeitung, No. 16, 17 April 2002, p. 1.
62. IMS Health (2000): Pharmaceutical Pricing Update. Taken from PhRMA (2001): http://www.phrma.org, including information updated in 2001, accessed on 31 March 2003.
63. Intercantonal Office for the Control of Medicines (Interkantonale Kontrollstelle für Heilmittel (2002): Public Information, http://www.iks.ch, accessed September 2002.
64. Interpharma (2001): Pharma-Markt Schweiz. Basel.
65. Jaikumar, R.; Upton, D. M. (1993): The Coordination of Global Manufacturing. In: Bradley, P.; Hausman, J.; Nolan, R. (Eds.): Globalization, Technology, and Competition, Harvard Business School Press: Boston MA.
66. Jakob, R. (2003): Eines von 47 Biotechunternehmen hat ein erfolgreiches Produkt. In: New Management, No. 3, pp. 10-13.
67. Kollmer, H.; Dowling, M. (2004): Licensing as a Commercialisation Strategy for New Technology-based Firms. In: Research Policy, Vol. 33, pp. 1141-1151.
68. KPMG (2002): Pharmaceuticals - Global Insights. By John Morris, Chair of the Europe, Middle East, South Asia, Africa Chemicals & Pharmaceuticals Practice. KPMG Report, February 2002.
69. La Merie (2007): R&D Pipeline News: Blockbuster Drugs 2006. July 6, 2007: http://www.pipelinereview.com, accessed September 2007.
70. Lehman Brothers (1999): Pharmaceutical Outsourcing Digest. 3 December 1999.
71. Leutenegger, J.-M. (1994): Wettbewerbsorientierte Informationssysteme in der Schweizer Pharma-Branche.
72. Lichtenberg, F. (1996): The Effect of Pharmaceutical Utilization and Innovation on Hospitalization and Mortality. National Bureau of Economic Research.
73. Lichtenberg, F. (2000): Are the Benefits of Newer Drugs Worth Their Costs? Evidence from the 1996 MEPS. In: Health Affairs, 20, 5, p. 241.
74. Lin, B.-W. (2001): Strategic Alliances and Innovation Networks in the Biopharmaceutical Industry. Institute of Technology Management, National Tsinghua University, Hsinchu, Taiwan.
75. Liu, C. X. and Xiao, P. G. (2002): Recalling the Research and Development of New Drugs Originating from Chinese Traditional and Herbal Drugs. In: Asian Journal of Drug Metabolism and Pharmacokinetics 2(2), pp. 133-156.
76. MedAdNews (2000): MedAd News, November 2000, as cited in: Accenture (2002): Commercial and R&D: Reinventing the relationship. Pharmaceuticals & medical products. Accenture White Paper.
77. MedAdNews (2007): Top 50 Pharmaceutical Companies, MedAdNews, September 2007.
78. Megantz, R. C. (2002): Technology Management - Developing and Implementing Effective Licensing Programs. New York: John Wiley and Sons.
79. Mueller, B. (2000): Schering: Synchronised Drug Development. In: Boutellier, R.; Gassmann, O.; von Zedtwitz, M. (Editors): Managing Global Innovation. 2nd edition. Heidelberg: Springer, pp. 249-257.
80. National Science Board (1996): Science & Engineering Indicators - 1996, NSB 96-21. Washington D. C.: U. S. Government Printing Office.
81. Nefiodow, L. A. (1990): der fünfte Kontradieff, Frankfurt.
82. Newman, D. J.; Cragg, G. M.; Snader, K. M. (2003): Natural Products as Sources of New Drugs over the Period 1981-2002. In: Journal of Nat. Prod. 66, pp. 1022-1037.
83. Nightingale, P. (2000): Economies of Scale in Experimentation: Knowledge and Technology in Pharmaceutical R&D. In: Industrial and Corporate Change, 9, 2, pp. 315-359.
84. Nonaka, I.; Takeuchi, H. (1995): The Knowledge-Creating Company. How Japanese Companies Create the Dynamics of Innovation. Oxford: New York.
85. NZZ (2002): der Novartis-Hauptsitz bleibt in Basel. Neue Zürcher Zeitung, 16 May 2002, p. 29.
86. OECD (1999): OECD Health Data. http://www.oecd.org/statistics, accessed September 2002.
87. OECD (2000): OECD Health Data. http://www.oecd.org/statistics, accessed February 2003.
88. OECD (2002): Science, Technology and Industry Outlook: Drivers of Growth: Information Technology, Innovation, and Entrepreneurship. Special Issue of the STI Outlook. OECD, Paris.
89. Paetz, O; Reepmeyer, G. (2003): F&E-Allianzen in der Arzneimittelentwicklung. Paper presented at Doctoral Seminar at the University of St. Gallen. June 2003, St. Gallen.
90. Pearce, R. D.; Singh, S. (1990): The Internationalisation of Research and Development by Multinational Enterprises: A Firm-level Analysis of Determinants. No. 145, GB-Whiteknights.
91. Pharma Information (2001): Swiss Health Care and Pharmaceutical Market. Edition 2001. Interpharma: Basel.
92. Pharma Information (2002): Swiss Health Care and Pharmaceutical Market. Edition 2002. Interpharma: Basel.
93. Pfeiffer, P. (2000): Sicherung von F&E-Kompetenz in multinationalen Pharmaunternehmen. Dissertation at the University of St. Gallen, Dissertation-No. 2362.
94. Pfiffner, M.; Stadelmann, P. D. (1995): Arbeit und Management in der Wissensgesellschaft. Dissertation at the University of St. Gallen.
95. Pfizer (1999): The Pfizer Journal, Vol. 3, Iss. 2.
96. PhRMA (2001): http://www.phrma.org, including information updated in 2001, accessed on 31 March2003.
97. PhRMA (2002): Pharmaceutical Research and Manufacturers of America. Industry Profile 2002.
98. PhRMA (2003): Pharmaceutical Research and Manufacturers of America, PhRMA Annual Membership Survey.
99. PhRMA (2004): Pharmaceutical Research and Manufacturers of America. Industry Profile 2004.
100. PhRMA (2007): Pharmaceutical Research and Manufacturers of America. Industry Profile 2007.
101. Porter, M. E. (1985): Competitive Advantage: Creating and Sustaining Superior Performance. Macmillan: New York.
102. Recombinant Capital (2005): Analyst's Notebook. Trends. http://www.recap.com/consulting.nsf/ANB-tab-trends? openform, accessed 11 February 2005.
103. Reepmeyer, G. (2005): Risk-sharing in the Pharmaceutical Industry - The Case of Out-licensing. Physica-Verlag: Heidelberg.
104. Reuters (2002): Pharmaceutical Innovation - An Analysis of Leading Companies and Strategies. Reuters Business Insight, Healthcare.
105. Reuters (2003a): The Blockbuster Drug Outlook to 2007: Identifying, Creating and Maintaining the Pharmaceutical Industry's Growth Drivers. Reuters Business Insight, Healthcare.
106. Reuters (2003b): Patent Protection Strategies: Maximizing Market Exclusivity. Reuters Business Insight, Healthcare.
107. Reuters (2003c): Pharmaceutical R&D Outsourcing Strategies - An Analysis of Market Drivers and Resistors to 2010. Reuters Business Insight, Healthcare.
108. Robbins-Roth, C. (2001): Zukunftsbranche Biotechnologie. Gabler.
109. Rothaermel, F. T. (2001): Complemetary Assets, Strategic Alliances, and the Incumbent's Advantage: An Empirical Study of Industry and Firm Effects in the Biopharmaceutical Industry. In: Research Policy, Vol. 30, pp. 1235-1251.
110. Saftlas, H. (2001): Industry Surveys, Healthcare: Pharmaceuticals. Standard & Poors: New York, 27 December 2001, p. 32.
111. Savioz, P. (2002): Technology Intelligence in Technology-based SMEs - Conceptual Design and Implementation. Zürich.
112. Schlatter, R. (2002): Pharmamarkt wächst rasant. Handelszeitung, No. 16, 17 April2002, p. 8.
113. Shane, S. (1992): Why do Some Societies Invent more than Others? In: Journal of Business Venturing, 7, pp. 29-46.
114. Shane, S. (1993): Cultural Influences on National Rates of Innovation. In: Journal of Business Venturing, 8, pp. 59-73.
115. Speedel (2004): Introducing the Speedel Group. Company presentation. http://www.speedelgroup.com, accessed on 10 September 2004.
116. SSCI (2000): http://www.sgci.ch, accessed September 2002.
117. SSCI (2002): http://www.sgci.ch, accessed September 2002.
118. Standort Schweiz (2003): Biotechnology http://www.standortschweiz.ch/ seco/internet/en/technologies/biotechnology/index.html, accessed 3 February 2003.
119. Swissmedic (2002): http://www.swissmedic.ch, accessed September 2002.
120. Swiss Scientific Council (1999): Fakten & Bewertungen 4/99. In: Pharma Information (2002); based upon Science, Vol. 725, 7 February 1997.
121. Thiel, K. A. (2004): Good-bye Columbus! New NRDOs forego discovery. In: Nature Biotechnology, Vol. 22, No. 9, pp. 1087-1092.
122. Thurow, L. (1996): The Future of Capitalism. Penguin.
123. VIPS (2002): Arzneitmittelmarkt Schweiz 2001: Wachstum durch innovative Arzneimittel. In: VIPS, Pharma Direkt, No. 13, March 2002.
124. Von Zedtwitz, M. (1999): Managing Interfaces in International R&D. Dissertation at the University of Gallen, Dissertation-No. 2315.
125. Von Zedtwitz, M.; Gassmann, O. (2002): Market versus Technology Drive in R&D Internationalization: Four Different Patterns of Managing Research and Development. In: Research Policy, 31, 4, pp. 569-588.
126. Von Zedtwitz, M.; Gassmann, O.; Reepmeyer, G.; (2003): Managing Pharmaceutical R&D - The Case of Switzerland. R&D Management Conference, Manchester, July 2003.
127. Völker, R. (1999): Wertorientiertes Controlling der Produktentwicklung. Kostenrechnungspraxis, 43, 1999, 4, pp. 201-208.
128. Völker, R. (2001): Planung und Steuerung von Entwicklungsprojekten in der Pharmabranche. In: Gassmann, O.; Kobe, C.; Voit, E. (Eds.): High-Risk-Projekte. Springer: Berlin, Heidelberg, New York, pp. 231-247.
129. Wang, A.; Von Zedtwitz, M. (2005): Developing the Pharmaceutical Business in China - the Case of Novartis. In: Festel, G.; Kreimeyer, A.; Oels, U.; von Zedtwitz, M. (Eds.): The Chemical and Pharmaceutical Industry in China - Challenges and Threats for Foreign Companies. Springer: Heidelberg. 109-119.
130. Webber, D. E. (2005): China's Approach to Innovative Pharmaceutical R&D: a Review. In: Festel, G.; Kreimeyer, A.; Oels, U.; von Zedtwitz, M. (Eds.): The Chemical and Pharmaceutical Industry in China - Challenges and Threats for Foreign Companies. Springer: Heidelberg. 121-131.
131. West, J. (1998): Building a High-Performing Team. In: Cleland, D. (Ed.): Field Guide to Project Management. Wiley: New York, pp. 239-254.
132. WGZ Bank (2002): Branchenanalyse Life Science. WGZ Report, Oktober 2002. Düsseldorf.
133. Whittaker, E.; Bower, D. J. (1994): A Shift to External Alliances for Product Development in the Pharmaceutical Industry. In: R&D Management, Vol. 24, No. 3, pp. 249-260.
134. Windhover (2000): Opportunism Knocks. Windhover's Review of Emerging Medical Ventures. Vol. 5, No. 4, pp. 32. http://www.windhover.com/contents/ monthly/exex/e-2000900064.htm, accessed on 19 December 2004.
135. Windhover (2003): In-licensing: Still a difficult model. Windhover's Review of Emerging Medical Ventures. Vol. 8, No. 10. http://www.windhover.com/ contents/monthly/exex/e-2003900172.htm, accessed on 19 December 2004.
136. Wood Mackenzie (2003a): As cited in presentation by F. Humer, CEO of Roche, June 2003.
137. Wood Mackenzie (2003b): As cited in company presentation by Speedel, February 2004.
138. WTO (2002): http://www.wto.org, accessed 18 February 2003.
139. Zambrowicz, B. P.; Sands, A. T. (2003): Knockouts Model The 100 Best-Selling Drugs - Will They Model The Next 100? In: Nature Reviews Drug Discovery, 2, January 2003, pp. 38-51.
140. Zanetti, P.; Steiner, U. (2001): ektorstudie Pharma Europa - Biotech als Hoffnungsträger. Leu Investment Research: Zürich.
141. Zeller, C. (2001): Globalisierungsstrategien - der Weg von Novartis. Springer: Heidelberg.